US 12,109,263 B2
Integrin agonists or activating compounds and methods for making and using same
Robert W Strozier, Houston, TX (US)
Filed by 7 Hills Pharma LLC, Houston, TX (US)
Filed on Sep. 10, 2021, as Appl. No. 17/471,922.
Claims priority of provisional application 63/076,595, filed on Sep. 10, 2020.
Prior Publication US 2022/0118086 A1, Apr. 21, 2022
Int. Cl. A61K 39/39 (2006.01); A61K 31/16 (2006.01); A61K 31/381 (2006.01); A61K 31/404 (2006.01); A61K 31/44 (2006.01); A61K 31/4436 (2006.01); A61K 31/4439 (2006.01); A61K 39/00 (2006.01); A61K 47/60 (2017.01); A61P 37/04 (2006.01)
CPC A61K 39/39 (2013.01) [A61K 31/16 (2013.01); A61K 31/381 (2013.01); A61K 31/404 (2013.01); A61K 31/44 (2013.01); A61K 31/4436 (2013.01); A61K 31/4439 (2013.01); A61K 39/0011 (2013.01); A61K 47/60 (2017.08); A61P 37/04 (2018.01); A61K 2039/55511 (2013.01)] 13 Claims
 
1. A composition comprising:
one or more antigens, and
one or more integrin activating or agonist compounds of the general Formulas:

OG Complex Work Unit Chemistry
wherein:
the R1 and R2 groups are independently a —(CH2)-aryl group, or a —(CH2)-heterocyclylaryl group, or the R1 and R2 groups combine to form a fused heterocyclylaryl group including at least one nitrogen-containing aryl group, and
n independently is an integer having a value between 1 and 6;

OG Complex Work Unit Chemistry
wherein:
the R1 and R2 groups are independently a —(CH2)-aryl group, or a —(CH2)-heterocyclylaryl group, or the R1 and R2 groups combine to form a fused heterocyclylaryl group including at least one nitrogen-containing aryl group, and
n independently is an integer having a value between 1 and 6;

OG Complex Work Unit Chemistry
wherein:
the R1 and R2 groups are independently a —(CH2)-aryl group, or a —(CH2)-heterocyclylaryl group, or the R1 and R2 groups combine to form a fused heterocyclylaryl group including at least one nitrogen-containing aryl group, and
n independently is an integer having a value between 1 and 6;

OG Complex Work Unit Chemistry
wherein:
the R1 and R2 groups are independently a —(CH2)-aryl group, or a —(CH2)-heterocyclylaryl group, or the R1 and R2 groups combine to form a fused heterocyclylaryl group including at least one nitrogen-containing aryl group, and
n independently is an integer having a value between 1 and 6;

OG Complex Work Unit Chemistry
wherein:
the R1 and R2 groups are independently a —(CH2)-aryl group, or a —(CH2)-heterocyclylaryl group, or the R1 and R2 groups combine to form a fused heterocyclylaryl group including at least one nitrogen-containing aryl group, and
n independently is an integer having a value between 1 and 6;

OG Complex Work Unit Chemistry
wherein:
the R1 and R2 groups are independently a —(CH2)-aryl group, or a —(CH2)-heterocyclylaryl group, or the R1 and R2 groups combine to form a fused heterocyclylaryl group including at least one nitrogen-containing aryl group, and
n independently is an integer having a value between 1 and 6;

OG Complex Work Unit Chemistry
wherein:
the R1 and R2 groups are independently a —(CH2)-aryl group, or a —(CH2)-heterocyclylaryl group, or the R1 and R2 groups combine to form a fused heterocyclylaryl group including at least one nitrogen-containing aryl group, and
n independently is an integer having a value between 1 and 6; and

OG Complex Work Unit Chemistry
wherein:
the R1 and R2 groups are independently a —(CH2)-aryl group, or a —(CH2)-heterocyclylaryl group, or the R1 and R2 groups combine to form a fused heterocyclylaryl group including at least one nitrogen-containing aryl group, and
n independently is an integer having a value between 1 and 6,
wherein:
the one or more integrin activating or agonist compounds may be administered before, during, and/or after the administration of the one or more antigens, and
the one or more integrin activating or agonist compounds activate one or more integrins.